Zeldox Bold Interaction Warning, Not Black Box, Needed For QTc - Committee
Executive Summary
Labeling for Pfizer's Zeldox (ziprasidone) should clearly warn against combination use with other drugs that may prolong the QTc interval, but a black box may not be necessary, FDA's Psychopharmacological Drugs Advisory Committee suggested July 19.
You may also be interested in...
Pfizer And GSK Call For Early Risk Tests; Sign Of Further Vioxx Fallout?
GlaxoSmithKline will launch a risk assessment program that will allow company researchers to more rapidly recognize safety signals
Pfizer And GSK Call For Early Risk Tests; Sign Of Further Vioxx Fallout?
GlaxoSmithKline will launch a risk assessment program that will allow company researchers to more rapidly recognize safety signals
Pfizer Ziprasidone Labeling Stops Short Of Second-Line Use; QT Effect Noted
Labeling for Pfizer's ziprasidone (Zeldox) recommends that doctors first consider prescribing antipsychotic agents associated with lower rates of QTc prolongation, but stops short of a second-line designation for the drug.